1. Histones and Their Modifications in Ovarian Cancer – Drivers of Disease and Therapeutic Targets
   Deborah J. Marsh et al, 2014, Frontiers in Oncology CrossRef
2. Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents
   Shipeng He et al, 2018, Journal of Medicinal Chemistry CrossRef
3. Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines
   Katharina Stenzel et al, 2017, Journal of Medicinal Chemistry CrossRef
4. Strategy for Traceless Codrug Delivery with Platinum(IV) Prodrug Complexes Using Self-Immolative Linkers
   Violet Eng Yee Lee et al, 2021, Inorganic Chemistry CrossRef
5. Priming with HDAC Inhibitors Sensitizes Ovarian Cancer Cells to Treatment with Cisplatin and HSP90 Inhibitors
   Ana J. Rodrigues Moita et al, 2020, International Journal of Molecular Sciences CrossRef
6. Epigenetic Therapy Augments Classic Chemotherapy in Suppressing the Growth of 3D High-Grade Serous Ovarian Cancer Spheroids over an Extended Period of Time
   Michelle Bilbao et al, 2021, Biomolecules CrossRef